Pure Global AI
NCT06296160Recruiting

A Simplified Lung Ultrasound Guided Management Protocol Of Pulmonary Congestion in Hemodialysis

Role of Lung Ultrasound in the Assessment and Management of Pulmonary Congestion in Chronic Hemodialysis Patients: A Randomized Controlled Study
Hamad Medical CorporationClinicalTrials.govother
Study focus
Drug/Device/Intervention
Intervention Group
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Hamad Medical Corporation
Location
Bruxelles, Belgium
Timeline & enrollment
Phase
N/A
Start date
May 28, 2023
End date
May 22, 2024
Enrollment
100 participants
Primary outcome

Assess the effectiveness of adding B-line score evaluation through lung ultrasound to the standard of care to improve pulmonary congestion (measured by B lines score) in hemodialysis patients

Summary

Pulmonary congestion secondary to volume overload or interstitial tissue inflammation is
 common in chronic hemodialysis patients. This pulmonary congestion occurs mainly during the
 period between dialysis sessions and is an independent risk factor for cardiovascular event
 morbidity and mortality in this population. The evaluation of this pulmonary congestion and
 the estimation of the dry weight of hemodialysis patients according to conventional methods
 represent a real challenge for clinical nephrologists. Lung ultrasound is a new diagnostic
 approach validated in the assessment of pulmonary congestion. It would allow a better
 assessment of dry weight in chronic hemodialysis patients based on the results of preliminary
 studies, including our latest pilot study. However, there is little evidence comparing this
 novel approach to traditional approaches.

ICD-10 classifications
Chronic kidney disease, stage 1Chronic kidney disease, stage 5Chronic kidney disease, stage 2Chronic kidney disease, stage 3Chronic kidney disease, stage 4
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06296160
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06296160 through Pure Global AI's free database. This phase not specified trial is sponsored by Hamad Medical Corporation and is currently Recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.